PD-1 blockade induces responses by inhibiting adaptive immune resistance

Paul C. Tumeh (), Christina L. Harview, Jennifer H. Yearley, I. Peter Shintaku, Emma J. M. Taylor, Lidia Robert, Bartosz Chmielowski, Marko Spasic, Gina Henry, Voicu Ciobanu, Alisha N. West, Manuel Carmona, Christine Kivork, Elizabeth Seja, Grace Cherry, Antonio J. Gutierrez, Tristan R. Grogan, Christine Mateus, Gorana Tomasic, John A. Glaspy, Ryan O. Emerson, Harlan Robins, Robert H. Pierce, David A. Elashoff, Caroline Robert and Antoni Ribas ()
Additional contact information
Paul C. Tumeh: University of California Los Angeles (UCLA)
Christina L. Harview: University of California Los Angeles (UCLA)
Jennifer H. Yearley: Merck & Co
I. Peter Shintaku: University of California Los Angeles (UCLA)
Emma J. M. Taylor: University of California Los Angeles (UCLA)
Lidia Robert: University of California Los Angeles (UCLA)
Bartosz Chmielowski: University of California Los Angeles (UCLA)
Marko Spasic: University of California Los Angeles (UCLA)
Gina Henry: University of California Los Angeles (UCLA)
Voicu Ciobanu: University of California Los Angeles (UCLA)
Alisha N. West: University of California Los Angeles (UCLA)
Manuel Carmona: University of California Los Angeles (UCLA)
Christine Kivork: University of California Los Angeles (UCLA)
Elizabeth Seja: University of California Los Angeles (UCLA)
Grace Cherry: University of California Los Angeles (UCLA)
Antonio J. Gutierrez: University of California Los Angeles (UCLA)
Tristan R. Grogan: University of California Los Angeles (UCLA)
Christine Mateus: Gustave Roussy and INSERM U981, Villejuif, Paris Sud, France
Gorana Tomasic: Gustave Roussy and INSERM U981, Villejuif, Paris Sud, France
John A. Glaspy: University of California Los Angeles (UCLA)
Ryan O. Emerson: Adaptive Biotechnologies
Harlan Robins: Adaptive Biotechnologies
Robert H. Pierce: Merck & Co
David A. Elashoff: University of California Los Angeles (UCLA)
Caroline Robert: Gustave Roussy and INSERM U981, Villejuif, Paris Sud, France
Antoni Ribas: University of California Los Angeles (UCLA)

Nature, 2014, vol. 515, issue 7528, 568-571

Abstract: The dynamics of T-cell responses are investigated in tumour tissue from patients with advanced melanoma who were treated with a PD-1-blocking monoclonal antibody, revealing that clinical efficacy of the treatment correlates with increased frequencies of pre-existing CD8+ T cells and PD-1 and PD-L1 expression.

Date: 2014
References: Add references at CitEc
Citations: View citations in EconPapers (33)

Downloads: (external link)
https://www.nature.com/articles/nature13954 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:515:y:2014:i:7528:d:10.1038_nature13954

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature13954

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().